Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSW80U)

• Drug Name: VM-202 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Phase 3	[1]
Diabetic foot ulcer	BD54	Phase 3	[2]
Peripheral arterial disease	BD4Z	Phase 3	[3]
Peripheral neuropathy	8C0Z	Phase 3	[4]
Amyotrophic lateral sclerosis	8B60.0	Phase 2	[5]

• Cross-matching ID: TTD Drug ID: DMSW80U

Molecule-Related Drug Atlas

Drug(s) Targeting Hepatocyte growth factor (HGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Donaperminogene seltoplasmid	DMH8IT5	Diabetic foot ulcer	BD54	Phase 3	[7]
ANG-3777	DMGP8WX	Delayed graft function	4B24.0	Phase 3	[8]
Ficlatuzumab	DMG65WH	Multiple myeloma	2A83	Phase 2	[9]
Collategene	DM27H0P	Peripheral Ischemic Ulcers	BD41	Phase 2	[10]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[9]
ABI-011	DM1KD7U	Lymphoma	2A80-2A86	Phase 1	[9]
TAK-701	DML3M0O	Advanced malignancy	2A00-2F9Z	Phase 1	[11]
Rilotumumab	DMD8ZSW	Grade IV malignant glioma	2A00.0	Discontinued in Phase 2	[12]
N,O6-Disulfo-Glucosamine	DMYCV7U	Discovery agent	N.A.	Investigative	[13]
O2-Sulfo-Glucuronic Acid	DME78MS	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Modulator	[6]

References

• [1] ClinicalTrials.gov (NCT02427464) Phase 3 Gene Therapy for Painful Diabetic Neuropathy. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
• [7] Clinical pipeline report, company report or official report of ViroMed.
• [8] Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.
• [11] Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
• [12] Clinical pipeline report, company report or official report of Amgen (2009).
• [13] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.